NetraMark and CAMH Secure Award to Enhance AI in Mental Health

NetraMark Holdings Inc., a leader in artificial intelligence (AI) for clinical trials, and the Centre for Addiction and Mental Health (CAMH) in Toronto have been awarded the Ontario Research Fund – Research Excellence (ORF-RE) Award. This recognition, announced on December 16, 2025, highlights innovative partnerships that drive research excellence and technological advancement in Ontario.

The collaboration will utilize NetraMark’s AI platform, known as NetraAI, within CAMH’s secure high-performance computing environment. This advanced system will analyze genetic and epigenetic data from studies on schizophrenia and major depressive disorder, with the goal of identifying patient subpopulations that clarify biological subtypes in these psychiatric conditions. By doing so, the project aims to enhance precision treatment strategies for affected individuals.

Dr. James Kennedy, Head of the Tanenbaum Centre for Pharmacogenetics at CAMH, emphasized the significance of the collaboration, stating, “This partnership integrates NetraMark’s unique AI approach with CAMH’s extensive genomic and clinical datasets. The insights generated will advance our understanding of the genes that influence treatment response, enabling more personalized care for patients battling complex mental health issues.”

Dr. Joseph Geraci, Founder and Chief Scientific & Technology Officer of NetraMark, expressed pride in being recognized with this award and highlighted the potential of the partnership. “Combining CAMH’s datasets with NetraAI’s explainable AI framework allows us to uncover biologically relevant subpopulations that traditional analytics often miss. We believe this work will contribute to next-generation precision-medicine approaches for mental health and improve clinical trial outcomes.”

The initiative will also evaluate an additional dataset from the Ontario Health Insurance Plan (OHIP) to conduct cost-effectiveness analyses and assess the broader implications of personalized patient care on the health system.

About the Organizations Involved

CAMH is Canada’s largest mental health and addiction teaching hospital and a leading research centre in the field. The institution integrates clinical care, research, education, policy development, and health promotion to transform the lives of those affected by mental illness and addiction. Fully affiliated with the University of Toronto, CAMH also serves as a Pan American Health Organization/World Health Organization Collaborating Centre.

NetraMark focuses on developing innovative Generative Artificial Intelligence and machine learning solutions targeted at the pharmaceutical industry. Its unique topology-based algorithm enables the analysis of patient data into meaningful subsets, facilitating improved classification of diseases and patient sensitivity to treatments.

As this collaboration unfolds, both organizations aim to advance the understanding of mental health disorders and enhance the effectiveness of treatment strategies through the application of AI-driven insights.

This partnership represents a significant step toward revolutionizing how psychiatric disorders are understood and treated, which could ultimately lead to better health outcomes for patients worldwide.